phosphoramidon and tachykinin-neuropeptide-gamma

phosphoramidon has been researched along with tachykinin-neuropeptide-gamma* in 2 studies

Other Studies

2 other study(ies) available for phosphoramidon and tachykinin-neuropeptide-gamma

ArticleYear
Characterization of tachykinin receptors mediating bronchomotor and vasodepressor responses to neuropeptide gamma and substance P in the anaesthetized rabbit.
    Pulmonary pharmacology & therapeutics, 1998, Volume: 11, Issue:1

    The effects of i.v. injections of two endogenous tachykinins, substance P (SP) and neuropeptide gamma and the highly selective tachykinin agonists [Sar9,Met(O2)11]-SP, [Lys5,MeLeu9, Nle10]-NKA(4-10) and senktide, on total lung resistance (RL), dynamic lung compliance (Cdyn) and systemic blood pressure, were compared in the anaesthetized rabbit. Senktide, the NK-3 receptor selective agonist, had no effect on RL, Cdyn or blood pressure. The other four agonists caused dose-dependent increases in RL and Cdyn, with [Sar9,Met(O2)11]-SP being the most potent agonist in producing changes in the absence of phosphoramidon. This suggested that NK-1 receptors play an important role in these responses. [Sar9, Met(O2)11]-SP, SP and neuropeptide gamma also decreased blood pressure. Phosphoramidon (1 mg/kg) potentiated the changes in RL and Cdyn evoked by [Sar9,Met(O2)11]-SP and SP, with very marked enhancement of responses to neuropeptide gamma. Responses to [Lys5, MeLeu9,Nle10]-NKA(4-10) were unaffected, suggesting that this NK-2 selective agonist may not be catabolized by neutral endopeptidase (NEP). In the presence of phosphoramidon, the non-peptide tachykinin NK-1 receptor selective antagonist CP 96345 (80 nmol/kg) reduced all responses to [Sar9,Met(O2)11]-SP and SP, whereas the NK-2 selective antagonist SR 48968 (40 nmol/kg) inhibited the bronchomotor but not the vasodepressor responses to neuropeptide gamma and [Lys5,MeLeu9, Nle10]-NKA(4-10). The fall in blood pressure induced by neuropeptide gamma was diminished by CP 96345, whereas bronchoconstriction was unaffected, indicating possible differences in NK-1 receptors in the vasculature and airways. Electrical stimulation of the distal ends of vagus nerves caused increases in RL which were abolished by atropine (1 mg/kg).

    Topics: Anesthesia; Animals; Benzamides; Biphenyl Compounds; Bronchoconstriction; Drug Interactions; Glycopeptides; Neprilysin; Neurokinin-1 Receptor Antagonists; Peptide Fragments; Piperidines; Protease Inhibitors; Rabbits; Receptors, Neurokinin-1; Receptors, Neurokinin-2; Substance P; Tachykinins; Vagus Nerve; Vasoconstriction

1998
Effects of SR 48968 on the neuropeptide gamma-induced contraction of the human isolated bronchus.
    Fundamental & clinical pharmacology, 1994, Volume: 8, Issue:1

    Neuropeptide gamma (NP gamma) induced a contractile response of the human isolated bronchus which was potentiated by the neutral endopeptidase inhibitor, phosphoramidon, but was not modified by atropine and indomethacin. NP gamma was 3.31-fold more potent than NKA. Contractile response curves to NP gamma were shifted to the right and maximal responses reduced by the non-peptide NK2-receptor antagonist, SR 48968. The pKB of SR 48968 (8.94 +/- 0.18, n = 15), calculated according to Kenakin (1987) was very close to that reported for [Nle10]-NKA (4-10), a specific agonist of neurokinin NK2-receptors (8.86 +/- 0.13, n = 13), suggesting that the contractile effects of NP gamma on the human isolated bronchus were mediated through NK2A-receptors.

    Topics: Benzamides; Bronchi; Bronchoconstriction; Culture Techniques; Dose-Response Relationship, Drug; Drug Interactions; Glycopeptides; Humans; Peptide Fragments; Piperidines; Receptors, Tachykinin; Tachykinins; Thermolysin

1994